|

GB5005 CART Clinical Trials

1 actively recruiting trial

Also known as: GB5005 chimeric antigen receptor T-cell injection

Pipeline

Phase 1: 1

Top Sponsors

  • The First Affiliated Hospital of Xiamen University1

Indications

  • Chimeric Antigen Receptor T-cell1
  • Non-hodgkin Lymphoma,B Cell1
  • Relapsed Non-Hodgkin Lymphoma1
  • Non-hodgkin Lymphoma1
  • Refractory Lymphoma1

Other1 trial

GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL
Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.